Finally, FBW7 2R-mutant and not FBW7 wildtype overexpression sensitized HCT116 cells to increasing doses of Taxol (Figure 5C) and provides proof-of-concept evidence that suggests mitigating FBW7 protein levels in chemotherapy resistance might be an interesting therapeutic target particularly in cancer patients with FBW7 wildtype genotype. The gene discussed is FBXW7; the disease is cancer.